EGFR and non-small cell lung carcinoma: A recent randomized phase III clinical trial (Northern Radiation Oncology Group of China-002) evaluated the efficacy and safety of first-line thoracic radiotherapy (TRT) combined with EGFR-tyrosine kinase inhibitors (TKIs) in patients with oligo-organ metastatic non-small-cell lung cancer (NSCLC) harboring EGFR-mutations, compared with TKI monotherapy.